anti programmed cell death protein 1 pd 1  (Bio X Cell)

Journal: Journal for Immunotherapy of Cancer

Article Title: Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy

doi: 10.1136/jitc-2025-012969

Figure Lengend Snippet: MCMV T cells are highly activated and cytotoxic within tumors. Immunophenotyping and cytokine production analysis of the TILs described in (25 days post-tumor implantation). (n=5/group). (A) Representative histograms of m45-specific CD8 T cells isolated from tumors (top) and MFI quantification (bottom). (B) Tumors were subjected to CD45+TIL magnetic separation and the purified cells were incubated with the six MCMV peptides for 4 hours, in the presence of GolgiPlug. The graphs show IFN-γ and TNF production in CD8 or CD4 Tconv cells. Results were compared by one-way ANOVA with Tukey correction. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ANOVA, analysis of variance; Gzm A and B, granzymes A and B; IFN, interferon; LAG3, lymphocyte activation gene 3 ; MCMV, murine cytomegalovirus; MFI, mean fluorescence intensity; Prf, perforin; PD-1, programmed cell death protein-1; Tconv, conventional T cell; TILs, tumor-infiltrating lymphocytes; TIM3, T cell immunoglobulin and mucin domain 3; TNF, tumor necrosis factor.

Article Snippet: When indicated, mice were intraperitoneally injected with anti-programmed cell death protein-1 (PD-1) (10 mg/kg two times a week, Bio X Cell, 29F.1A12), anti-Interleukin 10 Receptor (IL10R) (200 μg, once a week, Bio X Cell, 1B1.3A), anti-CD8 (200 μg, two times a week, Bio X Cell, YTS 169.4), anti-CD4 (100 μg two times a week, Bio X Cell, GK1.5) antibodies, or gemcitabine (5 mg/kg, two times a week, Selleck Chem).

Techniques: Tumor Implantation, Isolation, Purification, Incubation, Activation Assay, Fluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity

doi: 10.1007/s00262-025-04111-2

Figure Lengend Snippet: Inosine suppresses the antitumor effects of anti-programmed cell death protein 1 (anti-PD-1) antibody in a mouse CT-26 subcutaneous model. a Tumor growth curve of mice treated with PBS + IgG (black), PBS + anti-PD-1 (red) and inosine + anti-PD-1 (blue). Data are expressed as means with SEM from 9 to 11 mice per group. b Tumor growth curves of individual mice. c Area under the tumor growth curve. Each dot represents an individual value. d Pictures of resected tumors at the end of the experiment. Blanks indicate the disappearance of the tumor. e Number of responders and non-responders

Article Snippet: Fig. 6 Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody overcomes the inhibitory effects of inosine in combination with anti-programmed cell death protein 1 (PD-1) antibody in a mouse CT-26 subcutaneous tumor model. a Tumor growth curve of mice treated with PBS (black), inosine + anti-PD-1 + IgG (blue), or inosine + anti-PD-1 + anti-CTLA-4 (magenta).

Techniques:

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity

doi: 10.1007/s00262-025-04111-2

Figure Lengend Snippet: Upregulation of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression by the combination of inosine and anti-programmed cell death protein 1 (anti-PD-1) antibody. a Immunostaining of resected tumor tissue with anti-CD3. Left: representative micrographs. Scale bar = 200 µm. Right: number of CD3 + cells/mm 2 . Data are expressed as means with SEM from four mice per group. ns, not significant. b Relative gene expression of FoxP3 in tumor tissues from mice treated with PBS + anti-PD-1 and inosine + anti-PD-1 quantified through RT-qPCR analysis. Data are expressed as means with SEM from 4 to 5 mice. Numbers indicate p values. c Percentage of CD4 + FoxP3 + T cells in spleen and CD3 + cells from tumor model mice at the end of the experiment. Data are expressed as means with SEM from 9 to 11 mice. Numbers indicate p values. d Expression of CTLA-4 in CD4 + (left) and CD8 + (right) splenic T cells. Data are expressed as means with SEM from 9 to 11 mice. MFI, mean fluorescence intensity. e Expression of CTLA-4 in CD4 + T (left), CD8 + T (middle), and Treg (right) cells in lymph nodes. Numbers indicate p values. * P < 0.05 by Student’s t-test

Article Snippet: Fig. 6 Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody overcomes the inhibitory effects of inosine in combination with anti-programmed cell death protein 1 (PD-1) antibody in a mouse CT-26 subcutaneous tumor model. a Tumor growth curve of mice treated with PBS (black), inosine + anti-PD-1 + IgG (blue), or inosine + anti-PD-1 + anti-CTLA-4 (magenta).

Techniques: Expressing, Immunostaining, Gene Expression, Quantitative RT-PCR, Fluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity

doi: 10.1007/s00262-025-04111-2

Figure Lengend Snippet: Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody overcomes the inhibitory effects of inosine in combination with anti-programmed cell death protein 1 (PD-1) antibody in a mouse CT-26 subcutaneous tumor model. a Tumor growth curve of mice treated with PBS (black), inosine + anti-PD-1 + IgG (blue), or inosine + anti-PD-1 + anti-CTLA-4 (magenta). The inosine-treated groups received intraperitoneal injections (150 µg per mouse) of anti-PD-1 and mouse IgG or anti-CTLA-4 on days 4, 11, 18, and 25. Data are expressed as means with SEM from 10 mice per group. b Area under the tumor growth curve. Each dot represents an individual value. Numbers indicate p values from Dunn’s multiple comparison test. c Tumor growth curves of individual mice. d Number of responders and non-responders. e Pictures of resected tumors at the end of the experiment. Blanks indicate the disappearance of the tumor. f Tumor growth curve of mice treated with anti-PD-1 + anti-CTLA-4 (green) or inosine + anti-PD-1 + anti-CTLA-4 (magenta). Data points represent mean tumor volumes ± SEM at each time point for each treatment group (n = 8–9). Solid lines indicate group-wise means of observed values, and dashed lines represent predicted tumor growth curves estimated by a linear mixed-effects model (LMM), incorporating fixed effects of treatment, time (Days), and their interaction. The LMM revealed a significant interaction between treatment and time (Days × Group: coefficient = − 22.49, p = 0.012), indicating that inosine treatment significantly attenuated tumor growth over time. g Tumor growth curves of individual mice

Article Snippet: Fig. 6 Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody overcomes the inhibitory effects of inosine in combination with anti-programmed cell death protein 1 (PD-1) antibody in a mouse CT-26 subcutaneous tumor model. a Tumor growth curve of mice treated with PBS (black), inosine + anti-PD-1 + IgG (blue), or inosine + anti-PD-1 + anti-CTLA-4 (magenta).

Techniques: Comparison